Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer…
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease…
